NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock
April 28, 2020 09:44 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare...
NeuBase Therapeutics Announces Proposed Public Offering of Common Stock
April 27, 2020 16:01 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 27, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare...
NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL™ Platform
March 31, 2020 07:00 ET
|
NeuBase Therapeutics, Inc.
Demonstrates broad biodistribution, including across the blood-brain barrier into the central nervous system, and into skeletal muscle, in non-human primates (“NHPs”) after systemic administration ...
NeuBase Therapeutics Reports Financial Results for the First Fiscal Quarter of 2020
March 26, 2020 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, March 26, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide...
NeuBase Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
February 21, 2020 16:50 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Feb. 21, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) announced today that it received a standard notification letter dated February...
NeuBase Therapeutics Reports Financial Results for Fiscal Year 2019
January 09, 2020 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Jan. 09, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies using its...
NeuBase Therapeutics Wins The Scientist’s Top 10 Innovations of 2019 Award for its Janus Base Technology
December 02, 2019 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Dec. 02, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to...
NeuBase Therapeutics to Present at Upcoming Investor Conferences in December
November 25, 2019 08:00 ET
|
NeuBase Therapeutics, Inc.
Evercore ISI HealthCONx Conference panel discussion at 12:30 p.m. ET on December 3rd Piper Jaffray 31st Annual Healthcare Conference presentation at 8:30 a.m. ET on December 4th PITTSBURGH, Nov. ...
NeuBase Therapeutics to Present at the Stifel 2019 Healthcare Conference
November 12, 2019 09:16 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to...
NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL™ Enabled Therapies
October 17, 2019 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Oct. 17, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to...